• Study of chemotherapy drug combination with or without heated chemotherapy in the abdomen for patients with advanced colon cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain

  • A study testing xanomeline tartrate and trospium chloride for treating agitation in patients with Alzheimer’s disease

    Recruiting

    3 1
    Investigated Diseases:
    Investigated Drugs:
    Czechia France Hungary Italy Poland

  • A study comparing datopotamab deruxtecan with durvalumab versus datopotamab deruxtecan alone for patients with PDL1-negative metastatic triple-negative breast cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany Spain

  • Study of luspatercept for patients with rare inherited anemias to reduce transfusion needs and improve hemoglobin levels

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Italy

  • A study comparing dotinurad and allopurinol for lowering uric acid levels in adults with gout and high uric acid in the blood.

    Recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Poland Spain

  • A Study of MAS825 in Children and Adults with Still’s Disease to Test How Well It Works and How Safe It Is

    Recruiting

    2 1 1 1
    Investigated Drugs:
    France Germany Italy The Netherlands Spain

  • A Study of Fesoterodine and 5-[(1R,5R)-3-Azabicyclo[3.

    Recruiting

    2 1
    Investigated Drugs:
    Bulgaria Czechia France Hungary Italy Poland +3

  • A study testing ASP5541 compared to abiraterone acetate in patients with advanced prostate cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Germany Italy Poland Spain

  • Study of romiplostim given before heart surgery in patients with low platelet counts to improve blood clotting after surgery

    Recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    France

  • Study of rituximab followed by cladribine for patients with relapsing-remitting multiple sclerosis with less than 10 years disease duration

    Recruiting

    2 1 1 1
    Investigated Drugs:
    Sweden

powered by